Systemic Sclerosis–ILD Highlights From EULAR 2021

Toby M. Maher, MD, PhD


June 21, 2021

Dr Toby M. Maher, director of the Interstitial Lung Disease Program at Keck School of Medicine, University of Southern California, offers insight on key findings on systemic sclerosis–associated interstitial lung disease (SSc-ILD) presented at the EULAR 2021 meeting.

First, Dr Maher discusses two papers related to the SENSCIS trial. One showed a clinically meaningful reduction in the rate of forced vital capacity (FVC) decline with therapy. The next showed that nintedanib-treated patients with no breathlessness did better than those who reported dyspnea.

Next, he reviews a study looking at the long-term benefits of proton pump inhibition (PPI) for SSc-ILD patients, which showed that PPI-treated patients had an approximately 5% lower risk for death or progression than patients who did not receive PPI therapy.

Dr Maher then discusses a study that aimed to understand the healthcare decision-making and thought process of SSc-ILD patients.

He closes his commentary by reviewing data from the Scleroderma Lung Study (SLS) I and II, which looked at how short-term changes in radiographic extent affects long-term outcomes. Researchers found that participants with an increase in QILD-WL scores had significantly worse long-term survival.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.